|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ILF3-DT |
Gene summary for ILF3-DT |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ILF3-DT | Gene ID | 147727 |
| Gene name | ILF3 divergent transcript | |
| Gene Alias | ILF3-AS1 | |
| Cytomap | 19p13.2 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 147727 | ILF3-DT | LZE4T | Human | Esophagus | ESCC | 3.33e-14 | 3.71e-01 | 0.0811 |
| 147727 | ILF3-DT | LZE7T | Human | Esophagus | ESCC | 6.28e-20 | 6.60e-01 | 0.0667 |
| 147727 | ILF3-DT | LZE8T | Human | Esophagus | ESCC | 2.13e-11 | 3.86e-01 | 0.067 |
| 147727 | ILF3-DT | LZE20T | Human | Esophagus | ESCC | 9.98e-09 | 2.71e-01 | 0.0662 |
| 147727 | ILF3-DT | LZE21D1 | Human | Esophagus | HGIN | 2.75e-06 | 5.71e-01 | 0.0632 |
| 147727 | ILF3-DT | LZE22D1 | Human | Esophagus | HGIN | 5.14e-03 | 1.63e-01 | 0.0595 |
| 147727 | ILF3-DT | LZE22T | Human | Esophagus | ESCC | 1.57e-03 | 3.36e-01 | 0.068 |
| 147727 | ILF3-DT | LZE24T | Human | Esophagus | ESCC | 1.70e-23 | 5.12e-01 | 0.0596 |
| 147727 | ILF3-DT | LZE22D3 | Human | Esophagus | HGIN | 4.92e-04 | 5.85e-01 | 0.0653 |
| 147727 | ILF3-DT | LZE21T | Human | Esophagus | ESCC | 2.35e-12 | 5.47e-01 | 0.0655 |
| 147727 | ILF3-DT | LZE6T | Human | Esophagus | ESCC | 9.07e-08 | 3.26e-01 | 0.0845 |
| 147727 | ILF3-DT | male-WTA | Human | Thyroid | PTC | 1.50e-26 | 3.51e-01 | 0.1037 |
| 147727 | ILF3-DT | nodule-WTA | Human | Thyroid | goiters | 1.05e-02 | 1.88e-01 | 0.0534 |
| 147727 | ILF3-DT | PTC01 | Human | Thyroid | PTC | 4.31e-39 | 7.07e-01 | 0.1899 |
| 147727 | ILF3-DT | PTC03 | Human | Thyroid | PTC | 6.94e-04 | 2.57e-01 | 0.1784 |
| 147727 | ILF3-DT | PTC04 | Human | Thyroid | PTC | 1.45e-16 | 3.71e-01 | 0.1927 |
| 147727 | ILF3-DT | PTC05 | Human | Thyroid | PTC | 1.10e-35 | 1.02e+00 | 0.2065 |
| 147727 | ILF3-DT | PTC06 | Human | Thyroid | PTC | 4.12e-52 | 1.08e+00 | 0.2057 |
| 147727 | ILF3-DT | PTC07 | Human | Thyroid | PTC | 4.01e-71 | 1.09e+00 | 0.2044 |
| 147727 | ILF3-DT | ATC09 | Human | Thyroid | ATC | 5.47e-05 | 2.42e-01 | 0.2871 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |